Skip to content
-

Our responsibility

Sustainability & ESG

We aspire to advance the standard of care for the benefit of people with skin conditions and improve accessibility of innovative treatments. At the same time, we are addressing other environmental, social and governance (ESG) risks and opportunities.
Driving responsible business
Business ethics are the foundation of our conduct, ensuring trust, transparency and integrity in the way we work
Advancing the standard of care
We are dedicated to providing innovative treatments, collaborations with healthcare stakeholders and advocating for skin conditions as public health priorities
Diversity Equity and Inclusion
We believe that a diverse, equitable and inclusive work environment that empowers individuals with diverse backgrounds, skills and perspectives is a catalyst for innovation, wellbeing and enhancing performance
Driving sustainable impact
We are dedicated to contributing to a more sustainable future for all
Patient Safety
We make patient safety our top priority
Our code of conduct
We do not compromise our commitment to integrity
HCPs and healthcare organizations
The expertise of healthcare professionals & healthcare organizations help us to improve patients’ quality of life

Our commitments

We are committed to acting as a responsible global citizen and supporting the United Nations' 17 Sustainable Development Goals (SDGs). We participate actively in selected ESG and sustainability fora and partner with organizations that share our objective of combating global warming and promoting responsible research, business and medicine production.

 

MEDIA INQUIRIES

UN GLOBAL COMPACT

A United Nations pact to encourage companies worldwide to adopt sustainable and socially responsible policies and to report on their implementation of the Ten Principles of the UN Global Compact. LEO Pharma has been a signatory of UN Global Compact since 2018

SCIENCE BASED TARGETS INITIATIVE (SBTi)

Champions science-based target setting as a powerful way of boosting organizations’ competitive advantage in the transition to the low-carbon economy. It is a collaboration between the Carbon Disclosure Project (CDP), World Resources Institute (WRI), the World Wide Fund for Nature (WWF) and the United Nations Global Compact (UNGC). LEO Pharma had its emissions reduction targets validated by SBTi in 2022

MARSEILLE DECLARATION

The company-signatories of this declaration share common values and believe that the welfare of animals used in the research and production of medicines and vaccines requires the greatest consideration. This work demands application of high and most consistent standards of animal welfare and laboratory animal science regardless of where it is performed. LEO Pharma became a signatory of the Marseille Declaration in 2022

OTHER INITIATIVES

Announced in 2021, LEO Pharma's Diversity, Equity & Inclusion manifesto, Curiosity Beyond, encourages LEO Pharma's employees to embrace their differences and explore beyond the obvious. In 2024, LEO Pharma will conduct a Double Materiality Assessment in preparation for the new Corporate Sustainability Reporting Directive (CSRD). In 2026, LEO Pharma will be required to meet CSRD requirements in its annual report (reflecting results for the fiscal year 2025).